Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Proc Natl Acad Sci U S A ; 116(52): 26181-26186, 2019 Dec 26.
Article in English | MEDLINE | ID: mdl-31871174

ABSTRACT

Biomedical research is at a critical juncture, with an aging population increasingly beset by chronic illness and prominent failures to translate research from "bench to bedside." These challenges emerge on a background of increasing "silo-ing" of experiments (and experimenters)-many investigators produce and consume research conducted in 1, perhaps 2, species-and increasing pressure to reduce or eliminate research on so-called "higher" mammals. Such decisions to restrict species diversity in biomedical research have not been data-driven and increase the risk of translational failure. To illustrate this problem, we present a case study from neuroscience: cholinergic suppression in the cortex. In all mammals studied so far, acetylcholine reduces activity in some cortical neurons. Comparative anatomical studies have shown that the mechanism behind this suppression differs between species in a manner that would render drug treatments developed in nonprimate species entirely ineffective if applied to primates (including humans). Developing clinical interventions from basic research will always require translation, either between species (e.g., using a mouse model of a human disease) or within a species (using a subset of humans as a representative sample for all humans). We argue that successful translation will require that we 1) be data-driven in our selection of species for study; 2) use (with careful attention to welfare) animals that minimize the translation gap to humans; and 3) become agile at translation, by resisting the pressures to narrow our focus to a small number of organisms, instead using species diversity as an opportunity to practice translation.

3.
Mayo Clin Proc ; 89(10): 1389-96, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25171823

ABSTRACT

OBJECTIVE: To explore the self-expressed desire for, envisioned reaction to, and basic understanding of presymptomatic Alzheimer disease (AD)-related genetic and biomarker tests. PATIENTS AND METHODS: The Alzheimer's Prevention Registry is an online community of people at least 18 years of age who are interested in AD prevention research for purely informational purposes or to be considered for possible research participation in future studies. Information about presymptomatic testing and an online multiple choice format survey were posted from November 1, 2012, through June 20, 2013, on the registry website. RESULTS: Of 4036 respondents, 80.8% (3195/3952) wanted genetic testing if paid by insurance and 58.7% (2261/3851) if it would cost them at least $100. A total of 80.2% (3112/3879) wanted biomarker testing. If at high risk for AD, 90.5% (3478/3841) endorsed that they would "pursue a healthier lifestyle," but 11.6% (427/3706) endorsed "seriously consider suicide." The implication of a positive genetic test result was incorrectly understood by 13.1% (500/3812) and 32.6% (1255/3848) failed to view a positive biomarker test result as evidence of increased risk for or the presence of AD. CONCLUSION: Despite efforts to increase public awareness of AD, our survey results suggest that greater education of the public is needed. Interested patients should probably undergo psychological screening to identify those at high risk of adverse psychological outcomes, and disclosure of presymptomatic test results should be anchored to tangible constructive action plans, such as healthy lifestyle changes, long-term care planning, and, when available and appropriate, participation in research trials.


Subject(s)
Alzheimer Disease/diagnosis , Attitude to Health , Genetic Predisposition to Disease , Genetic Testing/methods , Population Surveillance/methods , Alzheimer Disease/epidemiology , Alzheimer Disease/genetics , Arizona/epidemiology , Female , Humans , Male , Middle Aged , Prevalence , Retrospective Studies
4.
Cell Stem Cell ; 12(3): 285-91, 2013 Mar 07.
Article in English | MEDLINE | ID: mdl-23472870

ABSTRACT

The nature of compensation for women who donate eggs (oocytes) for research remains a contentious issue internationally. This position paper lays out the arguments for, and discusses the arrangements in which, a modest payment might be ethically justifiable.


Subject(s)
Oocytes , Stem Cell Research/ethics , Female , Humans , Tissue and Organ Procurement/ethics
5.
BMC Med Ethics ; 9: 4, 2008 Feb 22.
Article in English | MEDLINE | ID: mdl-18294373

ABSTRACT

BACKGROUND: Research ethicists have recently declared a new ethical imperative: that researchers should communicate the results of research to participants. For some analysts, the obligation is restricted to the communication of the general findings or conclusions of the study. However, other analysts extend the obligation to the disclosure of individual research results, especially where these results are perceived to have clinical relevance. Several scholars have advanced cogent critiques of the putative obligation to disclose individual research results. They question whether ethical goals are served by disclosure or violated by non-disclosure, and whether the communication of research results respects ethically salient differences between research practices and clinical care. Empirical data on these questions are limited. Available evidence suggests, on the one hand, growing support for disclosure, and on the other, the potential for significant harm. METHODS: This paper explores the implications of the disclosure of individual research results for the relationship between research and clinical care through analysis of research-based cancer genetic testing in Ontario, Canada in the late 1990s. We analyze a set of 30 interviews with key informants involved with research-based cancer genetic testing before the publicly funded clinical service became available in 2000. RESULTS: We advance three insights: First, the communication of individual research results makes research practices seem like clinical services for our respondents. Second, while valuing the way in which research enables a form of clinical access, our respondents experience these quasi-clinical services as inadequate. Finally, our respondents recognize the ways in which their experience with these quasi-clinical services is influenced by research imperatives, but understand and interpret the significance and appropriateness of these influences in different ways. CONCLUSION: Our findings suggest that the hybrid state created through the disclosure of research results about individuals that are perceived to be clinically relevant may produce neither sufficiently adequate clinical care nor sufficiently ethical research practices. These findings raise questions about the extent to which research can, and should, be made to serve clinical purposes, and suggest the need for further deliberation regarding any ethical obligation to communicate individual research results.


Subject(s)
Genetic Research/ethics , Genetic Testing , Neoplasms/genetics , Research Personnel/ethics , Researcher-Subject Relations/ethics , Truth Disclosure/ethics , Canada , Humans , Moral Obligations , Narration , Ontario , Qualitative Research , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...